Review Article
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis
Table 1
Treatment recommendations for nontuberculous mycobacteria, according to 2007 American Thoracic Society Guidelines.
| | Initial therapy for nodular/bronchiectatic disease | Initial therapy for cavitary disease | Severe disease or previously treated disease |
| Mycobacterium avium complex | Clarithromycin 1,000 mg TIW or azithromycin 500–600 mg TIW Ethambutol 25 mg/kg TIW Rifampin 600 mg TIW | Clarithromycin 500–1,000 mg/d or azithromycin 250–300 mg/d Ethambutol 15 mg/kg/d Rifampin 450–600 mg/d ± Streptomycin or amikacin or none | Clarithromycin 500–1,000 mg/d or azithromycin 250–300 mg/d Ethambutol 15 mg/kg/d Rifabutin 150–300 mg/d or rifampin 450–600 mg/d ± Streptomycin or amikacin |
| Mycobacterium kansasii | Rifampin 10 mg/kg/d (maximum 600 mg/day) | Ethambutol 15 mg/kg/d | Isoniazid 5 mg/kg/d (maximum 300 mg) | Pyridoxine 50 mg/d |
|
|
TIW: three times in a week; d: day.
|